Record Information |
---|
Version | 1.0 |
---|
Created at | 2023-09-20 16:01:16 UTC |
---|
Updated at | 2023-09-20 16:01:58 UTC |
---|
NP-MRD ID | NP0331835 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Silibinin |
---|
Description | Silibinin is also known as silybin or legalon. Silibinin is a secondary metabolite. Secondary metabolites are metabolically or physiologically non-essential metabolites that may serve a role as defense or signalling molecules. In some cases they are simply molecules that arise from the incomplete metabolism of other secondary metabolites. It was first documented in 2021 (PMID: 34399200). Based on a literature review a significant number of articles have been published on Silibinin (PMID: 34222101) (PMID: 34221267) (PMID: 34209829) (PMID: 34208282) (PMID: 34181930). |
---|
Structure | [H]OC1=C([H])C(O[H])=C2C(O[C@]([H])(C3=C([H])C([H])=C4O[C@]([H])(C([H])([H])O[H])[C@]([H])(OC4=C3[H])C3=C([H])C([H])=C(O[H])C(OC([H])([H])[H])=C3[H])[C@@]([H])(O[H])C2=O)=C1[H] InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1 |
---|
Synonyms | Value | Source |
---|
Flavobin | ChEBI | Karsil | ChEBI | Silibinina | ChEBI | Silibinine | ChEBI | Silibininum | ChEBI | Silybin | ChEBI | Silymarin | ChEBI | Silymarin I | Kegg | Legalon | Kegg | 2,3 Dehydrosilybin | MeSH | 2,3-Dehydrosilybin | MeSH | Alepa forte | MeSH | Alepa-forte | MeSH | Ardeyhepan | MeSH | Cefasilymarin | MeSH | Hepa merz sil | MeSH | Hepa loges | MeSH | Hepa-merz sil | MeSH | HepaBesch | MeSH | Hepar pasc | MeSH | Hepar-pasc | MeSH | Heparsyx | MeSH | Heplant | MeSH | Lagosa | MeSH | Silibinin a | MeSH | Silibinin b | MeSH | Durasilymarin | MeSH | Hepa-loges | MeSH | Legalon forte | MeSH | Silibin | MeSH | Silybin a | MeSH | Silybin b | MeSH | Silybinin | MeSH | Silibinin | MeSH | Hepatos | MeSH |
|
---|
Chemical Formula | C25H22O10 |
---|
Average Mass | 482.4410 Da |
---|
Monoisotopic Mass | 482.12130 Da |
---|
IUPAC Name | (2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-3,4-dihydro-2H-1-benzopyran-4-one |
---|
Traditional Name | silibinin |
---|
CAS Registry Number | Not Available |
---|
SMILES | [H]OC1=C([H])C(O[H])=C2C(O[C@]([H])(C3=C([H])C([H])=C4O[C@]([H])(C([H])([H])O[H])[C@]([H])(OC4=C3[H])C3=C([H])C([H])=C(O[H])C(OC([H])([H])[H])=C3[H])[C@@]([H])(O[H])C2=O)=C1[H] |
---|
InChI Identifier | InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1 |
---|
InChI Key | SEBFKMXJBCUCAI-HKTJVKLFSA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 1H NMR Spectrum (1D, 600 MHz, C2D6OS, experimental) | Bgnzk | Not Available | Not Available | 2023-09-20 | View Spectrum | COSY NMR | [1H, 1H] NMR Spectrum (2D, 600 MHz, C2D6OS, experimental) | Bgnzk | Not Available | Not Available | 2023-09-20 | View Spectrum | HSQC NMR | [1H, 13C] NMR Spectrum (2D, 600 MHz, C2D6OS, experimental) | Bgnzk | Not Available | Not Available | 2023-09-20 | View Spectrum | HMBC NMR | [1H, 13C] NMR Spectrum (2D, 600 MHz, C2D6OS, experimental) | Bgnzk | Not Available | Not Available | 2023-09-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | Not Available |
---|
Chemical Taxonomy |
---|
Description | This compound belongs to the class of organic compounds known as flavonolignans. These are non-conventional lignans that derived from flavonoids. They are characterized by a p-dioxin ring substituted at one carbon atom by a C3C6 (phenylpropan) group and fused to the B-ring of the 2-phenylchromene moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lignans, neolignans and related compounds |
---|
Class | Flavonolignans |
---|
Sub Class | Not Available |
---|
Direct Parent | Flavonolignans |
---|
Alternative Parents | |
---|
Substituents | - Flavonolignan
- Hydroxyflavonoid
- 3-hydroxyflavonoid
- Flavanonol
- Flavanone
- 7-hydroxyflavonoid
- 5-hydroxyflavonoid
- Flavan
- Phenylbenzodioxane
- 2-phenylbenzo-1,4-dioxane
- Chromone
- 1-benzopyran
- Methoxyphenol
- Benzopyran
- Chromane
- Benzodioxane
- Benzo-1,4-dioxane
- Phenoxy compound
- Anisole
- Methoxybenzene
- Aryl alkyl ketone
- Aryl ketone
- Phenol ether
- Alkyl aryl ether
- 1-hydroxy-2-unsubstituted benzenoid
- Phenol
- 1-hydroxy-4-unsubstituted benzenoid
- Benzenoid
- Para-dioxin
- Monocyclic benzene moiety
- Vinylogous acid
- Secondary alcohol
- Ketone
- Polyol
- Organoheterocyclic compound
- Ether
- Oxacycle
- Alcohol
- Organooxygen compound
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Primary alcohol
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Predicted Properties | |
---|
General References | - Mohammadi H, Manouchehri H, Changizi R, Bootorabi F, Khorramizadeh MR: Correction to: Concurrent metformin and silibinin therapy in diabetes: assessments in zebrafish (Danio rerio) animal model. J Diabetes Metab Disord. 2020 Dec 7;20(1):1099. doi: 10.1007/s40200-020-00698-8. eCollection 2021 Jun. [PubMed:34222101 ]
- Zarpou S, Mosavi H, Bagheri A, Malekzadeh Shafaroudi M, Khonakdar-Tarsi A: NF-kappaB and NLRP3 gene expression changes during warm hepatic ischemia-reperfusion in rats with and without silibinin. Gastroenterol Hepatol Bed Bench. 2021 Summer;14(3):267-275. [PubMed:34221267 ]
- Rugamba A, Kang DY, Sp N, Jo ES, Lee JM, Bae SW, Jang KJ: Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells. Cells. 2021 Jun 29;10(7):1632. doi: 10.3390/cells10071632. [PubMed:34209829 ]
- Verdura S, Cuyas E, Ruiz-Torres V, Micol V, Joven J, Bosch-Barrera J, Menendez JA: Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals (Basel). 2021 Jun 11;14(6):559. doi: 10.3390/ph14060559. [PubMed:34208282 ]
- Liu X, Liu W, Wang C, Chen Y, Liu P, Hayashi T, Mizuno K, Hattori S, Fujisaki H, Ikejima T: Silibinin attenuates motor dysfunction in a mouse model of Parkinson's disease by suppression of oxidative stress and neuroinflammation along with promotion of mitophagy. Physiol Behav. 2021 Oct 1;239:113510. doi: 10.1016/j.physbeh.2021.113510. Epub 2021 Jun 25. [PubMed:34181930 ]
|
---|